Tactile Systems (TCMD) Oppenheimer 35th Annual Health Care MedTech and Services Conference summary

Business fundamentals and market opportunity

• Over 25 million U.S. patients are undiagnosed with lymphedema or bronchiectasis, with a $10 billion total addressable market (TAM).

• 2024 revenue reached $293 million, with 74% gross margins and $37.1 million adjusted EBITDA.

• Cash flow ended at $40 million, supported by scalable revenue cycle management and broad distribution.

• Served over 79,000 patients in 2024, with strong commercial viability and profitability.

• Large, underpenetrated populations and complex care journeys present significant growth opportunities.

Product innovation and patient engagement

• Launched Nimbl, a next-generation, portable platform for lymphedema, with strong adoption.

• Advanced and basic pump devices address different patient needs, covering upper/lower body and head/neck.

• Kylee app enhances patient engagement, allowing symptom tracking and communication with providers.

• Continued investment in digital strategies and patient-centric product development.

• Evidence supports clinical benefits, patient satisfaction, and compliance with therapies.

Market access, education, and reimbursement

• Focused on increasing access through patient and provider education, favorable reimbursement, and streamlined processes.

• Strong reimbursement environment, including support from the Lymphedema Treatment Act.

• Ongoing efforts to expand education via professional societies and internal programs.

• Distribution reach enhanced by investments in sales specialists and technology for documentation.

• Head and neck lymphedema data submitted for publication; new coding and coverage strategies underway.